RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Relmada Therapeutics Revenue 2024

Relmada Therapeutics Revenue

0 USD

Relmada Therapeutics Dividend yield

Ticker

RLMD

ISIN

US75955J4022

WKN

A2PSZF

In 2024, Relmada Therapeutics's sales reached 0 USD, a 0% difference from the 0 USD sales recorded in the previous year.

The Relmada Therapeutics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e663.51-
2028e398.21-
2027e111.38-
2026e47.07-
2025e--
2024e--
2023--
2022--
2021--
2020--
2019--
2018--
2017--
2016--
2015--
2014--
2013--
20120.01-
20110.01-

Relmada Therapeutics Aktienanalyse

What does Relmada Therapeutics do?

Relmada Therapeutics Inc is a biopharmaceutical company specializing in the development of medications for a variety of chronic pain and mental health disorders. The company is headquartered in New York, USA, and was founded in 2004. The history of Relmada Therapeutics Inc began with a focus on the development of NMDA receptor antagonists for the treatment of neuropathic pain. The company's main drug, d-Methadone, has been successfully tested in a Phase IIa clinical study and is now being tested in Phase IIb studies. Relmada Therapeutics Inc's business model is based on the development and commercialization of novel drugs targeting high medical needs. The company has a strong pipeline of pharmaceutical products in various clinical phases that can be used in pain management and mental health promotion. Relmada Therapeutics Inc generates revenue through the sale of patents and the out-licensing of their products to other pharmaceutical companies. In addition, the company pursues partnerships and joint ventures with other companies to further develop and market their products. Relmada Therapeutics Inc operates in three main divisions: pain therapy, mental health, and oncology. In pain therapy, the company has its main products, such as Oral Methadone and LevoCap ER, which help patients alleviate chronic pain. LevoCap ER is a long-acting, non-addictive pain medication that increases effectiveness and safety compared to other opioids. In the mental health field, Relmada Therapeutics Inc has developed QN-19, an overactive NMDA receptor blocker that represents a potential treatment option for depressive disorders. The company has also developed its new technology platform, mGluR2/3 agonists, which can be used in the treatment of anxiety and depression. In the oncology division, the company focuses on the development of innovative cancer treatments. The company is currently developing a new cancer drug that aims to overcome chemotherapy resistance. Relmada Therapeutics Inc is committed to providing innovative solutions to improve and enhance the quality of life for patients. The company relies on a strong research and development platform to develop medications targeting a variety of needs. The company is committed to continuing its research and development to provide innovative solutions that improve the treatment of chronic diseases. Answer: Relmada Therapeutics Inc is a biopharmaceutical company specializing in the development of medications for chronic pain and mental health disorders. The company is headquartered in New York, USA, and has a strong pipeline of pharmaceutical products in various clinical phases. They generate revenue through the sale of patents and partnerships with other companies, and their divisions focus on pain therapy, mental health, and oncology. They aim to provide innovative solutions to improve patient quality of life and continue research and development for better treatment options. Relmada Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Relmada Therapeutics's Sales Figures

The sales figures of Relmada Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Relmada Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Relmada Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Relmada Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Relmada Therapeutics Stock

How much revenue did Relmada Therapeutics generate this year?

Relmada Therapeutics has achieved a revenue of 0 USD this year.

How much was the turnover of the company Relmada Therapeutics compared to the previous year?

The revenue of Relmada Therapeutics has increased by 0% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Relmada Therapeutics?

The revenue of Relmada Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Relmada Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Relmada Therapeutics so important for investors?

The revenue of Relmada Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Relmada Therapeutics pay?

Over the past 12 months, Relmada Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Relmada Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Relmada Therapeutics?

The current dividend yield of Relmada Therapeutics is .

When does Relmada Therapeutics pay dividends?

Relmada Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Relmada Therapeutics?

Relmada Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Relmada Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Relmada Therapeutics located?

Relmada Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Relmada Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Relmada Therapeutics from 4/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/30/2024.

When did Relmada Therapeutics pay the last dividend?

The last dividend was paid out on 4/30/2024.

What was the dividend of Relmada Therapeutics in the year 2023?

In the year 2023, Relmada Therapeutics distributed 0 USD as dividends.

In which currency does Relmada Therapeutics pay out the dividend?

The dividends of Relmada Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Relmada Therapeutics

Our stock analysis for Relmada Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Relmada Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.